The administration of cholic acid supplements the bile acid pool in patients with HSD3B7 mutations, which impairs the conversion of cholesterol to bile acids in congenital bile acid synthesis defect type 1 (CBAS1). This therapeutic intervention bypasses the defective enzymatic pathway, directly addressing the metabolic deficiency to treat severe cholestasis and prevent liver damage.